Education
About Us
Working with TipRanks
Follow Us
ACELYRIN, INC. (SLRN)
NASDAQ:SLRN
SLRN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $7.25
Previous CloseN/A
Volume2.42M
Average Volume (3M)1.15M
Market Cap
$219.98M
Enterprise Value-$127.59M
Total Cash (Recent Filing)$73.89M
Total Debt (Recent Filing)$6.27M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Jun 12, 2025EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding100,907,200
10 Day Avg. Volume1,293,307
30 Day Avg. Volume1,154,850
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$20.00Price Target Upside817.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ACELYRIN, INC. News
PremiumCompany Announcements
ACELYRIN, INC. Announces Merger with Alumis Inc.---
Bulls Say, Bears Say
Bulls Say
Potential EfficacyThe Ph3 regimen of 100mg LD + 50mg Q2W could potentially increase drug exposure, possibly boosting its efficacy.
Safety ProfileLonigutamab demonstrates a promising safety profile with no hearing impairment, no hyperglycemia, and no elevation of circulating IGF1.
Bears Say
Dosing ConcernsConcerns exist on a more frequent dosing interval for lonigutamab versus subQ competition.
Investor ConcernsShares are weak post the disclosure on the selection of Q2W for the Ph3 dosing regimen and uncertainty surrounding efficacy expectations for a Ph3 dose not tested in the Ph1b/2 study.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SLRN FAQ
What was ACELYRIN, INC.’s price range in the past 12 months?
ACELYRIN, INC. lowest stock price was $1.84 and its highest was $7.25 in the past 12 months.
What is ACELYRIN, INC.’s market cap?
ACELYRIN, INC.’s market cap is $219.98M.
When is ACELYRIN, INC.’s upcoming earnings report date?
ACELYRIN, INC.’s upcoming earnings report date is Jun 12, 2025 which is in 57 days.
How were ACELYRIN, INC.’s earnings last quarter?
ACELYRIN, INC. released its earnings results on Mar 27, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.863 by -$0.167.
Is ACELYRIN, INC. overvalued?
According to Wall Street analysts ACELYRIN, INC.’s price is currently Undervalued.
Does ACELYRIN, INC. pay dividends?
ACELYRIN, INC. does not currently pay dividends.
What is ACELYRIN, INC.’s EPS estimate?
ACELYRIN, INC.’s EPS estimate is -0.73.
How many shares outstanding does ACELYRIN, INC. have?
ACELYRIN, INC. has 100,907,200 shares outstanding.
What happened to ACELYRIN, INC.’s price movement after its last earnings report?
ACELYRIN, INC. reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.863. Following the earnings report the stock price went up 3.937%.
Which hedge fund is a major shareholder of ACELYRIN, INC.?
Currently, no hedge funds are holding shares in SLRN
---
ACELYRIN, INC. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (817.43% Upside)
$20.00 (817.43% Upside)
Hedge Fund Trend
Decreased
By 357.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $68.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.40%
12-Months-Change
Fundamentals
Return on Equity
-44.54%
Trailing 12-Months
Asset Growth
-33.87%
Trailing 12-Months
Company Description
ACELYRIN, INC.
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.
---
SLRN Stock 12 Month Forecast
Average Price Target
$20.00
▲(817.43% Upside)
Technical Analysis
Astria Therapeutics
―
iTeos Therapeutics
―
Atea Pharmaceuticals
―
Compass Therapeutics
―
Candel Therapeutics
―
Best Analysts Covering SLRN
1 Year
1 Year Success Rate
2/16 ratings generated profit
1 Year Average Return
-50.78%
reiterated a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -50.78% per trade.
---